Gateway to Think Tanks
来源类型 | Report |
规范类型 | 报告 |
来源ID | RR-240-DH |
Pharmaceutical pricing: The use of external reference pricing | |
Kai Ruggeri; Ellen Nolte | |
发表日期 | 2013-06-04 |
出版年 | 2013 |
页码 | 59 |
语种 | 英语 |
结论 |
|
摘要 | External reference pricing, or international price comparison, is a common strategy to control prices of pharmaceuticals that are protected by intellectual property rights and benefit from a legal monopoly (in-patent drugs). In the UK negotiations are under way that seek to define new arrangements for the pricing of branded (new) medicines from 2014. The pharmaceutical market in the UK only accounts for a small proportion of global sales; however, UK prices are important as many countries reference their prices against those in the UK. This report seeks to contribute to our understanding of approaches to pharmaceutical pricing in high-income countries and the role of reference pricing as a means to determining pharmaceutical prices. Reviewing experiences in Canada, France, Germany, Italy, the Netherlands and Spain, we find high variability of external reference pricing across different settings and of the relative importance of this approach in comparison with other pricing strategies. There was also considerable variation in the terminology and practices used, and understanding the complexities of countries included in reference baskets for external pricing requires considerable semantic clarification. There was considerable overlap between countries that cross-reference, and it remains challenging to estimate the direct, immediate impact on external reference baskets. This review suggests that the international impact of pricing changes in the UK is likely to be minimal or indirect, largely because of the diverse ways in which reference pricing is implemented in the countries examined. |
目录 |
|
主题 | Canada ; France ; Germany ; Health Care Costs ; Health Care Price Competition ; Italy ; Netherlands ; Pharmaceutical Drugs ; Spain |
URL | https://www.rand.org/pubs/research_reports/RR240.html |
来源智库 | RAND Corporation (United States) |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/522281 |
推荐引用方式 GB/T 7714 | Kai Ruggeri,Ellen Nolte. Pharmaceutical pricing: The use of external reference pricing. 2013. |
条目包含的文件 | ||||||
文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
RAND_RR240.pdf(482KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
x1495315145413.jpg.p(1KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[Kai Ruggeri]的文章 |
[Ellen Nolte]的文章 |
百度学术 |
百度学术中相似的文章 |
[Kai Ruggeri]的文章 |
[Ellen Nolte]的文章 |
必应学术 |
必应学术中相似的文章 |
[Kai Ruggeri]的文章 |
[Ellen Nolte]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。